Gender differences in metabolic monitoring of second-generation antipsychotic prescription

Human Psychopharmacology

Volumn 23, Issue 6, 2008, Pages 471-474

  Verdoux, Hélène ^a,b   Boulon, Sophie ^a   Cougnard, Audrey ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

Clinical practice; Gender; Metabolic monitoring; Second generation antipsychotic

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL PRACTICE; FEMALE; FRANCE; GENDER BIAS; HUMAN; MALE; MEDICAL EDUCATION; METABOLIC PARAMETERS; MOOD DISORDER; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; QUESTIONNAIRE; SCHIZOPHRENIA; SCREENING;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS, DRUG; SEX CHARACTERISTICS;

EID: 51049114214     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.956     Document Type: Article

References (13)

1. American Psychiatric Association. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65: 267-272.
2. Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM. 2007. A UK audit of screening for the metabolic side effects of anti-psychotics in community patients. Schizophr Bull 33: 1397-1403.
3. Expert Consensus Meeting. 2004. Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry Suppl 47: S112-114.
4. Kilbourne AM, Post EP, Bauer MS, et al. 2007. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord 102: 145-151.
5. Marder SR, Essock SM, Miller AL, et al. 2004. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349.
6. Nasrallah HA, Meyer JM, Goff DC, et al. 2006. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86: 15-22.
7. Newcomer JW, Nasrallah HA, Loebel AD. 2004. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24: S1-6.
8. Newcomer JW, Sernyak MJ. 2007. Identifying metabolic risks with antipsychotics and monitoring and management strategies. J Clin Psychiatry 68: e17.
9. Sernyak MJ. 2007. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 68 (Suppl 4): 14-18.
10. StataCorp. 2005. Stata Statistical Software: Release 9.0. In:Stata Corporation, College Station, Texas.
11. Taylor D, Young C, Esop R, Paton C, Walwyn R. 2004. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 185: 152-156.
12. Voruganti LP, Punthakee Z, Van Lieshout RJ, et al. 2007. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. Schizophr Res 96: 215-222.
13. Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM. 2006. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J Clin Psychiatry 67: 1323-1326.